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AT2R-mediated regulation of Na-Cl cotransporter (NCC) and 
renal K excretion depends on the K channel, Kir4.1
Peng Wu1,#, Zhong-Xiuzi Gao1,#, Xin-Peng Duan2, Xiao-Tong Su1, Ming-Xiao Wang1, Dao-
Hong Lin1, Ruimin Gu2, and Wen-Hui Wang1
1Department of Pharmacology, New York Medical College, Valhalla, NY
2Department of Physiology, Harbin Medical University, Harbin, China
Abstract
Angiotensin II (AngII) type 2 receptor (AT2R) is expressed in the distal nephrons. The aim of the 
present study is to examine whether AT2R regulates Na-Cl cotransporter (NCC) and Kir4.1 of the 
distal convoluted tubule (DCT). AngII inhibited the basolateral 40 pS K channel (a Kir4.1/5.1 
heterotetramer) in the DCT treated with losartan but not with PD123319. AT2R agonist also 
inhibits the K channel, indicating that AT2R was involved in tonic regulation of Kir4.1. The 
infusion of PD123319 stimulated the expression of total NCC (tNCC) and phosphorylated NCC 
(pNCC) (Thr53) by a time-dependent way with the peak at 4 days. PD123319 treatment (4 days) 
stimulated the basolateral 40 pS K channel activity, augmented the basolateral K conductance and 
increased the negativity of DCT membrane. The stimulation of Kir4.1 was essential for 
PD123319-induced increase in NCC since inhibiting AT2R increased the expression of tNCC and 
pNCC only in WT but not in the kidney-specific Kir4.1 knockout (KS-Kir4.1 KO) mice. Renal 
clearance study showed that thiazide-induced natriuretic effect was larger in PD123319 treated 
mice for 4 days than untreated mice. However, this effect was absent in KS-Kir4.1 KO mice which 
were also Na wasting under basal conditions. Finally, application of AT2R antagonist decreased 
the renal ability of K excretion and caused hyperkalemia in WT but not in KS-Kir4.1 KO mice. 
We conclude that AT2R dependent regulation of NCC requires Kir4.1 in the DCT and that AT2R 
plays a role in stimulating K excretion by inhibiting Kir4.1 and NCC.
Keywords
Angiotensin II; Na transport; hypertension; hyperkalemia and hypokalemia
Introduction
It is well established that two types of angiotensin II (AngII) receptors, AT1R and AT2R, are 
expressed in the kidney and involved in the regulation of a variety of epithelial transport 
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processes (1–5). While the role of AT1R in regulating membrane transport in the kidney is 
extensively investigated (3–6), the role of AT2R in the regulation of Na and K transport is 
less well known. The deletion of AT2R has been shown to increase blood pressure, 
augmenting AngII-induced hypertension and causing renal Na retention (7–9). Conversely, 
the activation of AT2R has been shown to stimulate renal Na excretion and to lower blood 
pressure (10;11). For instance, stimulation of AT2R has been shown to promote natriuresis, 
an effect attributed to the inhibition of Na transport in the proximal tubule by NO-dependent 
pathway (11). Thus, the activation of AT2R is expected to antagonize the stimulatory effect 
of AT1R on renal Na transport (1). Not only regulating Na transport, AT2R-dependent 
signaling pathway may also play a role in the regulation of renal K excretion and K 
homeostasis (12). First, an increase in dietary K intake augmented the expression of AT2R in 
the renal tissue including cortical collecting duct (CCD). Second, AngII has been shown to 
stimulate ROMK channel (Kir1.1), a K secretory channel, only in animals on a high K (HK) 
diet (12). Since the inhibition of AT2R abolished the stimulatory effect of AngII on ROMK, 
this strongly suggests the possible role of AT2R in mediating renal K excretion in the 
aldosterone-sensitive distal nephron segments (ASDN) including distal convoluted tubule 
(DCT) and CCD. Immunostaining shows that AT2R is expressed in proximal tubules and the 
cortical portion of distal tubules (2). Since the DCT is a main component of the cortical 
portion of the distal nephrons, it raises the possibility that AT2R may regulate the membrane 
transport in the DCT. The DCT is responsible not only for the reabsorption of 5% filtered Na 
load but it also plays a key role in the regulation of renal K transport and K homeostasis 
since the DCT determines Na and volume delivery to the late ASDN (13;14). Previous 
studies have demonstrated that both apical NCC and basolateral Kir4.1 K channel play an 
essential role in mediating the membrane transport in the DCT (15–17). The deletion of 
Kir4.1 has been shown to inhibit NCC in the DCT and to increase ENaC and plasma 
aldosterone as compensation (16;18). Thus, the aim of the present study is to explore the 
role of AT2R in the regulation of NCC and Kir4.1 in the DCT.
Methods
The authors declare that all supporting data and detailed methods including animal 
preparation, electrophysiology, western blot and renal clearance method are available within 
the article and its online supplementary file.
Animals
Kcnj10flox/flox (WT) and inducible kidney-specific Kir4.1 knockout (KS-Kir4.1 KO) mice 
with C57BL/6 background were obtained as described previously (16). To generate KS-
Kir4.1 KO mice, mice expressing Pax8-rtTA and tet-on LC-1 transgene were crossed with 
Kcnj10flox/flox mice (detailed information is provided in supplement). The mice were fed 
with normal rodent chow diet and had free access to water. For perfusion of PD123319 (4 
¼g/min/kg BW) or vehicles, the mice were implanted subcutaneously with an osmotic mini-
pump (Model. 1007D, Alzet) for 1, 4 and 7 days, respectively. The animal use was approved 
by the independent Institutional Animal Care and Use Committee at New York Medical 
College.
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Angiotensin II, hydrochlorothiazide (HCTZ), CGP42112A, losartan and PD123319 were 
purchased from Sigma (St Louis, MO). The NCC antibody was a gift from Robert Hoover at 
Emory University, whereas antibody of phosphorylated NCC at threonine 53 (Thr53) was 
kindly provided by David H. Ellison at Oregon Health & Science University. The data are 
shown as mean ± SEM. We used the paired t test or one-way ANOVA test to determine the 
statistical significance.
Results
AT2R regulates the basolateral K channel in the DCT
We first performed the patch-clamp experiments to examine the effect of AngII on the 
basolateral 40 pS K channel (a Kir4.1/5.1 heterotetramer) in the DCT. The results 
summarized in Figure S1 depict that AngII had no significant effect on the K channel 
activity (control, 1.59±0.15; AngII, 1.42±0.13). We speculate that the AT1R signaling may 
antagonize AT2R effect or vise versa since both AT1R and AT2R are expressed in the distal 
nephrons (2). Thus, we examined the effect of 100 nmol/L AngII on the basolateral K 
channels in the presence of either PD123319 (an AT2R antagonist) or losartan (an AT1R 
antagonist), respectively. Figure 1A is a typical channel recording showing that the 
application of neither PD123319 (10 μmol/L) nor AngII (100 nmol/L)+PD123319 had a 
significant effect on the 40 pS K channel activity in the DCT. Figure 1B summarizes the 
results from five experiments showing that the 40 pS K channel activity defined by NPo was 
1.72±0.17 (control), 1.66±0.12 (PD123319) and 1.52±0.1 (AngII+PD123319), respectively. 
The results suggest that acute stimulation of AT1R does not affect the basolateral 40 pS K 
channel in the DCT. We next examined the effect of AngII on the basolateral 40 pS K 
channel in the DCT treated with losartan. Figure 1C is a recording demonstrating the effect 
of AngII on the basolateral 40 pS K channel. Application of losartan (10 μmol/L) alone had 
no significant effect on the 40 pS K channel since NPo with losartan treatment (1.75±0.2) 
was similar to the control value (1.73±0.17) (Figure 1D). However, in the presence of 10 
μmol/L losartan, AngII significantly inhibited the 40 pS K channel and the inhibitory effect 
of AngII on the 40 pS K channel was reversible since the washout largely restored the 
channel activity. Also, adding AT2R antagonist abolished the inhibitory effect of AngII
+losartan (NPo =1.58±0.16) (Figure 1D). Results are summarized in Figure 1D 
demonstrating that AngII decreased channel activity to 0.14±0.02 in the DCT treated with 
losartan (n=6). The notion that AT2R rather than AT1R is involved in tonic regulation of the 
basolateral K channel activity was also supported by the finding that application of 
CGP42112A (1 μmol/L), an AT2R agonist (19), inhibited the basolateral K channel in the 
DCT and decreased NPo to 0.37±0.15 (Figure 1D).
AT2R regulates NCC
The basolateral K channels in the DCT have been shown to play a key role in the regulation 
of thiazide-sensitive NCC by modulating the Cl-sensitive WNK pathway (16;20). Having 
demonstrated that AngII inhibited the basolateral Kir4.1/5.1 by AT2R, we next examined 
whether inhibiting AngII-AT2R pathway in vivo should affect NCC activity. Thus, we 
examined the expression of tNCC and pNCC in the mice which were continuously infused 
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with PD123319 (4 μg/min/kg BW) (a similar dose has been used to inhibit AT2R in vivo) 
through an osmotic mini-pump for 1, 4 and 7 days, respectively (21). Infusion of PD123319 
did not affect the food and water intakes in comparison to the control mice (vehicle) (Table 
S1) but it affected the expression of tNCC and pNCC (Figure 2). From the inspection of 
Figure 2A, it is apparent that the expression of both tNCC (150±10% of the control) and 
pNCC (175±10% of the control) was significantly increased in the mice treated with 
PD123319 infusion for 4 days (Figure 2B & C). Although both tNCC (125±10% of the 
control) and pNCC (135±8% of the control) were slightly decreased in the mice treated with 
7-day PD123319 treatment in comparison to 4 days, they were still significantly higher than 
that of the untreated control (Figure 2B & C). Figure 2D also shows that pNCC expression is 
slightly but significantly larger than tNCC in the mice treated with PD123319 for 4 days 
when pNCC value is normalized with tNCC (pNCC/tNCC ratios were 1.05±0.1, 1.17±0.1 
and 1.07±0.1 for 1 day, 4 days and 7 days PD123319, respectively). Moreover, the effect of 
PD123319 on NCC expression was specific since the inhibition of AT2R had no significant 
effect on the expression of NKCC2 and ENaC-α subunit (Figure S2). Thus, AT2R inhibition 
specifically stimulates NCC activity in the DCT.
Inhibition of AT2R increases Kir4.1 in the DCT
Previous studies have shown that a high basolateral K conductance was linked to a high 
NCC activity (16). Thus, we tested whether PD123319-induced stimulation of NCC was due 
to the augmentation of the basolateral K conductance in the DCT by examining the 
basolateral K channel activity in the mice treated with PD123319 for 4 days since it had the 
largest effect on NCC (Figure 2). From the inspection of Figure 3A, it is apparent that the 40 
pS K channel activity in the DCT of the mice treated with PD123319 for 4 days was 
significantly higher (2.16±0.2) than that of untreated control animals (1.53±0.12) (Table S2). 
Further analysis shows that PD123319-induced increase in the 40 pS K channel activity was 
the result of increasing channel open probability (control, 0.47±0.04; PD123319, 0.59±0.05) 
and the number of functional K channels in the membrane (Table S2). We found the 40 pS K 
channel in 44 patches from a total of 61 experiments (72%) in mice treated with AT2R 
antagonist whereas the probability of finding the 40 pS K channel was only 51% (43 patches 
with K channel from total 84 experiments) in the untreated group.
The possibility that the inhibition of AT2R for 4 days stimulated the basolateral K channels 
in the DCT was further suggested by measuring Ba (barium)-sensitive whole-cell K currents 
in the DCT of the mice treated with PD123319. Figure 3B is a recording showing the 
currents of DCT cells clamped from -100 mV to 100 mV with a ramp protocol from 
untreated control and PD123319-treated mice. As summarized in Figure 3C, the mean 
whole-cell K current at -60 mV was -1280±100 pA (n=6) in control (vehicle) mice and it 
was -1970±180 pA (n=6) in PD123319-treated mice. Because the basolateral K channels 
participate in generating the membrane potential of DCT cells, a stimulation of the 
basolateral K channels is expected to hyperpolarize DCT membrane. Thus, we measured the 
K-current (IK) reversal potential, which serves as an index of DCT membrane potential. 
Figure 3D is a perforated whole-cell recording showing current/voltage curve of the DCT 
with 140 mmol/L K in the pipette (intracellular solution) and 140 mmol/L Na+5 mmol/L K 
in the bath from the control and PD123319-treated mice. The results from seven experiments 
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are summarized in Figure 3C (lower panel) showing IK reversal potential of the DCT in the 
control mice (-63.7±1.9 mV) and in PD123319-treated mice (-72±2 mV). Thus, patch-clamp 
experiments confirm that the inhibition of AT2R for 4 days increases the basolateral K 
channel activity in the DCT and causes hyperpolarization of the membrane.
Kir4.1 is required for inhibiting AT2R-induced stimulation of NCC
If the activation of the basolateral Kir4.1/5.1 channels in the DCT is directly responsible for 
PD123319 perfusion-induced stimulation of NCC activity, we expect that PD123319 
treatment should have no effect on NCC in the absence of Kir4.1. Thus, we examined the 
effect of PD123319 infusion (4 days) on NCC expression in both WT and in KS-Kir4.1 KO 
mice. Figure 4 is a western blot showing the effect of PD123319 (4 days) on tNCC and 
pNCC in WT (Figure 4A) and in KS-Kir4.1 KO mice (Figure 4B). The normalized band 
intensity for pNCC and tNCC is summarized in Figures 4C and 4D, respectively. We 
confirm that PD123319 infusion for 4 days significantly increased the abundance of tNCC 
(150±10% of the control) and pNCC (175±10% of the control) in WT mice. The reason for 
paralleled changes in tNCC and pNCC is possibly due to unphosphorylated NCC is not 
stable (22). However, deletion of Kir4.1 not only decreased both tNCC (38±5% of WT) and 
pNCC (32±5% of WT) under control conditions (untreated) but also abolished the effect of 
PD123319 on tNCC (40±5% of WT) and pNCC (35±3% of WT). Also, PD123319 
treatment failed to cause hyperpolarization of the DCT membrane in KS-Kir4.1 KO mice 
(Figure S3). Thus, AT2R inhibition failed to stimulate NCC and to induce hyperpolarization 
of the DCT in KS-Kir4.1 KO mice.
The notion that Kir4.1 is essential for the activation of NCC induced by AT2R inhibition 
was also supported by renal clearance experiments in which HCTZ-induced natriuretic effect 
was examined. For the clearance study, the mice were intravenously perfused with isotonic 
saline for 4 hr (0.3 ml/1 hr) and urine collections started one hr after infusion of 0.3 ml 
saline. Figure 5A shows results from each individual experiment in which urinary Na 
excretion (ENa) was measured before and after a single dose of HCTZ (25 mg/kg BW) in 
WT mice and KS-Kir4.1 KO mice with or without PD123319 treatment. Figure 5B 
summarizes all above results showing that HCTZ-induced natriuretic effect (from 0.5±0.06 
to 2.82±0.14 μEq/min/100g BW) in PD123319-treated mice was significantly larger than 
those in the untreated group (from 0.7±0.14 to 1.95±0.21 μEq/min/100g BW). This finding 
is consistent with immunoblotting suggesting that PD123319 treatment for 4 days increases 
NCC activity. However, deletion of Kir4.1 not only increased basal level of ENa (1.15±0.06 
μEq/min/100g BW) and abolished HCTZ-induced natriuretic effect (HCTZ, 1.27±0.05 
μEq/min/100g BW), but also eliminated the effect of PD123319 treatment (control, 
1.23±0.11; HCTZ, 1.47±0.13 μEq/min/100g BW). This strongly suggests that AT2R 
inhibition-induced stimulation of NCC function is the result of the activation of basolateral 
Kir4.1 in the DCT. We also used renal clearance method to examine the acute effect of 
CGP42112A (AT2R agonist) at 1.5 mg/kg BW on ENa in WT and KS-Kir4.1 KO mice 
(Figure S4). AT2R agonist stimulated Na excretion (control, 0.61±0.06; CGP42112A, 
1.82±0.15 μEq/min/100g BW), the deletion of Kir4.1 attenuated CGP42112A-induced 
natriuretic effect (control, 1.24±0.11; CGP42112A, 2.03±0.17 μEq/min/100g BW) (Figure 
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S4A) since the net ENa induced by CGP42112A is smaller in KS-Kir4.1 KO mice than WT 
(WT, 1.21±0.11; KS-Kir4.1 KO, 0.79±0.06 μEq/min/100g BW, Figure S4B).
Inhibition of AT2R impairs K homeostasis
It is well established that NCC plays a key role in the regulation of K homeostasis (15). 
Thus, we next examined the effect of AT2R antagonist on urinary K excretion (EK) in WT 
mice and in KS-Kir4.1 KO mice using renal clearance method. Figure 6A shows the results 
from each individual experiment which are then summarized in Figure 6B demonstrating the 
mean value and statistical information. The application of HCTZ increased K excretion from 
0.52±0.03 to 1.10±0.02 μEq/min/100g BW in untreated WT mice and from 0.19±0.05 to 
0.82±0.11 μEq/min/100g BW in PD123319-treated WT mice. Moreover, from the inspection 
of Figure 6B it is apparent that basal level of EK in PD123319-treated mice was significantly 
lower than that of the untreated group (0.19±0.05 vs 0.52±0.03 μEq/min/100g BW). The 
notion that PD123319 treatment for 4 days impairs renal K excretion is also suggested by 
observations that PD123319 treatment significantly increased the plasma K concentration 
from 4.1±0.2 to 5.2±0.3 mmol/L (n=8) (Table S3) in WT mice. We also confirm the 
previous finding that the deletion of Kir4.1 caused K wasting in the mice with or without 
PD123319 treatment (Figure 6A). The results from 5 experiments are summarized in Figure 
6B showing that HCTZ did not significantly alter EK in KS-Kir4.1 KO mice treated with 
PD123319 (from 0.97±0.03 to 1.16±0.05 μEq/min/100g BW) or without (1.06±0.04 to 
1.20±0.07 μEq/min/100g BW). Consequently, KS-Kir4.1 KO mice were hypokalemic under 
control conditions (2.8±0.1 mmol/L) or during PD123319 treatment for 4 days (2.9±0.2 
mmol/L) (Table S3). Thus, PD123319 treatment (4 days) caused hyperkalemia in WT mice 
and this effect was absent in KS-Kir4.1 KO mice. Also, CGP42112A stimulates renal K 
secretion (0.57±0.02 to 1.10±0.10 μEq/min/100g BW) and this effect was abolished in KS-
Kir4.1 KO mice (1.10±0.1 to 1.27±0.1 μEq/min/100g BW) (Figure S4C), suggesting that 
Kir4.1 is required for AT2R agonist-induced stimulation of renal K excretion.
Discussion
In the present study, we observed that AngII inhibited the basolateral 40 pS K channel in the 
DCT treated with losartan, suggesting that AT2R is responsible for mediating the inhibitory 
effect of AngII on basolateral K channels in the DCT. This notion was also suggested by the 
observation that the infusion of PD123319 increased the basolateral K conductance in the 
DCT. The reason that acute application of AT2R antagonist had no effect on K channels is 
possibly due to the inactivated AT2R without AngII in the isolated DCT. This view is 
supported by the finding that AT2R agonist inhibits the K channel in the DCT. Although the 
inhibition of AT2R could indirectly enhance AT1R-dependent pathway, it is unlikely that 
AT1R was responsible for the upregulation of the basolateral 40 pS K channel activity since 
AngII had no effect on the 40 pS K channel in the DCT treated with PD123319. However, it 
is possible that the long-term stimulation of AT1R may be able to indirectly influence the 
basolateral K channel activity in the DCT. The stimulation of AT1R has been shown to 
increase Na transport in the thick ascending limb and in distal nephrons (6;23), and to 
stimulate ENaC in the CCD (5;24;25). Consequently, the stimulation of Na transport not 
only causes volume expansion but it may also increase renal K excretion in ASDN thereby 
Wu et al. Page 6













leading to hypokalemia which could also increase the basolateral K conductance. But, this 
possibility is largely excluded by the observation that the mice treated with AT2R inhibitor 
were hyperkalemic rather than hypokalemic. Thus, the results strongly suggest that AT2R 
rather than AT1R in the DCT is involved in mediating a tonic regulation of the basolateral 40 
pS K channel.
The basolateral 40 pS K channel in the DCT is composed of Kir4.1 (encoded by Kcnj10) 
and Kir5.1 (encoded by Kcnj16) and Kir4.1 is a key component for forming the basolateral 
K conductance because the deletion of Kcnj10 completely eliminates the basolateral K 
conductance (16;26;27). Since this 40 pS K channel is the only type of K channel in the 
basolateral membrane of the DCT (16), it is conceivable that a factor which regulates the 
basolateral 40 pS K channel activity should have a profound effect on the basolateral K 
conductance and the membrane potentials. Indeed, we observed that the inhibition of AT2R 
not only increased the basolateral K conductance but also hyperpolarized the DCT 
membrane. This suggests that AT2R plays a role in tonic regulation of the membrane 
potential in the DCT under a variety of physiological conditions.
A large body of evidence has suggested the membrane potential in the DCT plays an 
important role in the regulation of NCC activity such that an increase in the membrane 
negativity (hyperpolarization) stimulates, whereas a decrease in membrane negativity 
(depolarization) inhibits NCC activity (16;20;28;29). Our present study has also 
demonstrated that AT2R inhibition-induced hyperpolarization is correlated with an increase 
in NCC activity. The mechanism by which the membrane potential is linked to NCC 
expression is most likely due to the modulation of Cl-sensitive with-no-lysine kinase (WNK) 
which is activated by low intracellular Cl and inhibited by high intracellular Cl (20;30;31). It 
is well established that WNK activity plays a key role in increasing NCC activity by 
stimulating ste20-proline-and-alanine-rich kinase and oxidative-sensitive responsive kinase 
(32–36). Two lines of evidence suggest that the activation of Kir4.1 in the DCT is 
responsible for mediating the effect of AT2R on NCC. First, the AT2R inhibition 
significantly hyperpolarizes the DCT membrane and stimulates NCC. Second, PD123319 
infusion failed to stimulate NCC in KS-Kir4.1 KO mice in which the AT2R inhibition also 
did not cause hyperpolarization of the DCT. This finding also excludes the possibility that an 
indirect activation of AT1R, which has been shown to stimulate WNK4 (37), is responsible 
for PD123319 perfusion-induced stimulation of NCC expression. Thus, our results strongly 
suggest that the activation of the basolateral Kir4.1 in the DCT induced by AT2R inhibition 
is responsible for PD123319-induced increase in NCC expression and activity.
Recent developments in the field of renal K excretion have indicated that NCC activity in the 
DCT plays an important role in the regulation of K excretion and K homeostasis (20;38;39). 
For instance, an increase in dietary K intake suppresses the NCC activity thereby increasing 
Na and volume delivery to the late ASDN, whereas a decrease in dietary K intake stimulates 
the NCC activity thereby decreasing Na and volume delivery to the late ASDN. The role of 
NCC in regulating renal K secretion and K homeostasis is also convincingly established by 
human genetic and clinical studies demonstrating that an abnormal NCC activity is 
responsible for causing hyperkalemia or hypokalemia. For instance, 
pseudohypoaldosteronism type II (PHAII) or familial hyperkalemic hypertension (FHHt) is 
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caused by high activity of NCC (34;40;41), whereas hypokalemia in patients with Gitelman 
syndrome is due to the loss-of-function mutations of NCC (42). Indeed, our present study 
has also demonstrated that AT2R inhibition induced upregulation of NCC diminished renal 
ability for K excretion such that the mice treated with PD123319 were hyperkalemic. 
Moreover, we observed that hyperkalemia was more severe in the mice treated with 
PD123319 for 7 days than in those treated for 4 days (Figure S5). This hyperkalemia may be 
responsible for a compensatory decrease in NCC expression in the mice treated with 
PD123319 for 7 days.
Perspectives
The physiological significance of our finding is to illustrate a possible signaling pathway 
which mediates the effect of HK diet on the basolateral Kir4.1and apical NCC activity. 
Although it is demonstrated that increased dietary K intake inhibits the basolateral 
Kir4.1/5.1 K channels (29), the mechanism by which HK intake inhibits the basolateral 
Kir4.1 is not clear. It is possible that AT2R may be involved in mediating the effect of HK 
intake on the basolateral K channels in the DCT since HK intake has been shown to 
upregulate AT2R expression (12). An upregulation of AT2R in the DCT should lead to the 
inhibition of the basolateral K channel activity thereby depolarizing DCT membrane. A 
depolarization of the DCT inhibits NCC expression and increases the Na and volume 
delivery to the late ASDN. Since a HK intake is also expected to stimulate the expression of 
ROMK and ENaC (43–45), a high ENaC/ROMK activity and a high Na delivery should 
stimulate K secretion in the late ASDN. In addition, the present study suggests that the 
stimulation of AT2R in the kidney not only inhibits type III Na-H exchanger and Na-K-
ATPase in the proximal tubule but also NCC in the DCT(10). We conclude that AT2R plays 
a role in regulating NCC activity by modulating the basolateral Kir4.1 activity in the DCT 
and that AT2R plays a role in mediating renal K excretion and K homeostasis.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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1) What is New?
• Angiotensin II inhibits the basolateral Kir4.1 in the DCT by AT2R-pathway 
and the inhibition of AT2R hyperpolarizes DCT membrane.
• Inhibition of AT2R causes hyperkalemia and high NCC activity. This effect 
depends on the presence of Kir4.1 in the DCT because PD123319 did not 
increase NCC and failed to induce hyperkalemia in KS-Kir4.1 KO mice.
2) What is relevant?
• Stimulation of AT2R increases renal Na excretion and is antihypertensive. 
The finding that the inhibition of AT2R increases NCC activity is highly 
relevant for understanding the mechanism of AT2R-induced natriuretic effect.
• NCC plays a key role in regulating renal K excretion and maintaining K 
homeostasis while Kir.4.1 plays a key role in controlling NCC activity. The 
finding that AT2R is involved in the regulation of Kir4.1 and NCC is relevant 
for understanding an integrated mechanism of regulating K homeostasis.
Summary
AT2R plays a role in regulating NCC activity by modulating the basolateral Kir4.1 
activity in the DCT and that AT2R plays a role in mediating renal K excretion and K 
homeostasis.
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Figure 1. Stimulation of AT2R inhibits the basolateral Kir4.1/5.1 (40 pS) K channels in the DCT
(A) A recording shows the effect of 100 nmol/L angiotensin II (AngII) on the 40 pS K 
channel in the DCT treated with PD123319 (10 μmol/L). Three parts of the trace indicated 
by numbers are extended to show a fast time resolution. (B) A bar graph summarizes the 
results from 5 similar experiments. (C) A recording shows the effect of 100 nmol/L AngII 
on the 40 pS K channel in the DCT treated with losartan (10 μmol/L). Three parts of the 
trace indicated by numbers are extended to show a fast time resolution. (D) A bar graph 
summarizes the results from 6 similar experiments in which the effect of losartan, AngII
+losartan, PD123319+losartan+AngII and CGP42112A (1 μmol/L) on the basolateral 40 pS 
K channel in the DCT was examined. The experiments were performed in cell-attached 
patches at 0 mV and the channel closed line is indicated by “C”. “**” indicates a significant 
difference in comparison to other groups (P<0.01).
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Figure 2. Inhibition of AT2R increases the abundance of pNCC and tNCC
(A) Western blots show the abundance of phosphor-NCC (pNCCT53) and total NCC (tNCC) 
in mice treated with vehicle (control) and PD123319 (1 day, 4 days and 7 days), respectively. 
A bar graph summarizes the normalized (using GAPDH as a loading reference) band 
intensity of above results for pNCCT53 (B) and tNCC (C), respectively. (D) The normalized 
ratio between pNCC and tNCC in the mice treated with PD123319 for 1, 4 and 7 days, 
respectively. “*” indicates a significant difference in comparison to the control (P<0.05). 
PD123319 (4 μg/min/kg BW) was applied through an osmotic mini-pump.
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Figure 3. Inhibition of AT2R increases the Kir4.1/5.1 activity in the DCT
(A) Representative recordings show the activity of the basolateral 40 pS K channel in the 
DCT from mice treated with vehicle (control) and PD123319 for 4 days, respectively. The 
experiments were performed in cell-attached patches with 140 mmol/L K in the pipette and 
140 mmol/L Na+5 mmol/L K in the bath solution. The closed level is indicated by a dotted 
line and “C”. (B) A whole-cell recording showing Ba (barium)-sensitive K currents in the 
DCT of the mice treated with vehicle (control) and PD123319 for 4 days, respectively. The 
K currents were measured with a ramp protocol from -100 to 100 mV using symmetrical 
140 mmol/L KCl solution in the bath and pipette. (C) A bar graph (top panel) summarizes 
the results of experiments in which Ba-sensitive K currents of the DCT were measured at 
-60 mV from the PD123319-treated and untreated (control) mice (n=6). (D) K-current (IK) 
reversal potential of the DCT measured with perforated whole-cell recording in the mice 
treated with vehicle (control) or PD123319 for 4 days. The bath solution contains (in 
mmol/L) 140 NaCl and 5 KCl while the pipette solution has 140 KCl. A bar graph (low 
panel of Figure 3C) summarizes the results of above experiments (n=6). “*” means that the 
difference is significant in comparison to the control value (P<0.05). PD123319 (4 
μg/min/kg BW) was applied through an osmotic mini-pump.
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Figure 4. Inhibition of AT2R increases the abundance of pNCC and tNCC in WT mice but not in 
KS-Kir4.1 KO mice
Western blots show the abundance of phosphor-NCC (pNCCT53) and total NCC (tNCC) in 
WT mice (A) and in KS-Kir4.1 KO mice (B) treated with vehicle (control) and PD123319 
for 4 days, respectively. A bar graph summarizes the normalized band intensity of above 
results for pNCCT53 (C) and tNCC (D), respectively. “*” indicates a significant difference in 
comparison to the corresponding control (P<0.05). PD123319 (4 μg/min/kg BW) was 
applied through an osmotic mini-pump.
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Figure 5. Inhibition of AT2R upregulates NCC activity in WT mice but not in KS-Kir4.1 KO 
mice
(A) A line graph shows the results of each experiment in which urinary sodium excretion 
(ENa) was measured before and after a single dose of HCTZ (25 mg/kg BW) in WT mice 
and KS-Kir4.1 KO mice with (triangle) or without (circle) PD123319 infusion for 4 days. 
(B) A bar graph summarizes all above experiments. HCTZ-induced natriuretic effect was 
significantly different between control and PD123319 (PD) treated mice. The basal level of 
ENa of KS-Kir4.1 KO mice is significantly different in comparison to WT mice. PD123319 
(4 μg/min/kg BW) was applied through an osmotic mini-pump.
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Figure 6. Inhibition of AT2R diminishes the renal ability of K excretion
(A) A line graph shows the results of each experiment in which urinary potassium excretion 
(EK) was measured before and after a single dose of HCTZ (25 mg/kg BW) in WT mice and 
KS-Kir4.1 KO mice with (triangle) or without (circle) PD123319 treatment (PD) for 4 days. 
(B) A bar graph summarizes all above experiments shows the mean value and statistic 
information. The basal level of EK in PD123319 treated WT mice is significantly different 
from vehicle groups (control). PD123319 (4 μg/min/kg BW) was applied through an osmotic 
mini-pump.
Wu et al. Page 18
Hypertension. Author manuscript; available in PMC 2019 April 01.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
